跳转至内容
Merck

32483

Supelco

伏立康唑

VETRANAL®, analytical standard

别名:

2R,3S-2-(2,4-二氟苯基)-3-(5-氟嘧啶-4-基)-1-(1H-1,2,4-三唑-1-基)丁-2-醇, UK-109496

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C16H14F3N5O
分子量:
349.31
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

analytical standard

品質等級

產品線

VETRANAL®

儲存期限

limited shelf life, expiry date on the label

技術

HPLC: suitable
gas chromatography (GC): suitable

應用

forensics and toxicology
pharmaceutical (small molecule)

格式

neat

SMILES 字串

C[C@@H](c1ncncc1F)[C@](O)(Cn2cncn2)c3ccc(F)cc3F

InChI

1S/C16H14F3N5O/c1-10(15-14(19)5-20-7-22-15)16(25,6-24-9-21-8-23-24)12-3-2-11(17)4-13(12)18/h2-5,7-10,25H,6H2,1H3/t10-,16+/m0/s1

InChI 密鑰

BCEHBSKCWLPMDN-MGPLVRAMSA-N

正在寻找类似产品? 访问 产品对比指南

一般說明

Voriconazole is a second-generation triazole, and is derived from fluconazole. It has a broad and enhanced antifungal spectrum as compared to other older triazoles. It is mostly well tolerated and is available in both oral and intravenous formulations.

應用

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

生化/生理作用

伏立康唑是用于治疗严重真菌感染的抗真菌药。伏立康唑通过抑制 CYP450 依赖性 14-α甾醇脱甲基酶来抑制麦角固醇合成,从而导致真菌细胞膜中的麦角固醇减少。
It has been used as one of the constituent of YPD (1% yeast extract, 2% peptone, 2% glucose) liquid media.
Voriconazole is an antifungal used to treat serious fungal infections. Voriconazole inhibits ergosterol synthesis by inhibiting CYP450-dependent 14-a sterol demethylase resulting in a depletion of ergosterol in fungal cell membranes.

法律資訊

VETRANAL is a registered trademark of Merck KGaA, Darmstadt, Germany

象形圖

Skull and crossbonesHealth hazard

訊號詞

Danger

危險分類

Acute Tox. 3 Oral - Aquatic Chronic 3 - Carc. 2 - Muta. 2 - Repr. 2 - STOT RE 1 - STOT RE 2 Oral - STOT SE 2 Oral

標靶器官

Eyes, Liver,Kidney

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


Choose from one of the most recent versions:

分析证书(COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
Herbrecht, Raoul, et al.
The New England Journal of Medicine, 347 (6), 408-415 (2002)
Convergent evolution of calcineurin pathway roles in thermotolerance and virulence in Candida glabrata.
Chen, Ying-Lien, et al.
G3 (Bethesda, Md.), 2 (6), 675- 691 (2012)
Voriconazole: a new triazole antifungal agent.
Saravolatz, Louis D., Leonard B. Johnson, and Carol A. Kauffman.
Clinical Infectious Diseases, 36 (5), 630-637 (2003)
Kim Vanstraelen et al.
Antimicrobial agents and chemotherapy, 58(11), 6782-6789 (2014-09-04)
Setting the adequate dose for voriconazole is challenging due to its variable pharmacokinetics. We investigated the impact of hypoalbuminemia (<35 g/liter) on voriconazole pharmacokinetics in adult intensive care unit (ICU) patients treated with voriconazole (20 samples in 13 patients) as
Atsuko Sunada et al.
Ophthalmology, 121(10), 2059-2065 (2014-06-02)
To evaluate the effectiveness of topical agents for the treatment of Acanthamoeba keratitis (AK). Laboratory research. Fifty-six Acanthamoeba isolates from 56 patients with clinically proven AK were studied. The effectiveness of 7 agents against Acanthamoeba cysts was determined in vitro.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门